Risk Factors for Colonization with Extended-Spectrum β-Lactamase–producing Bacteria and Intensive Care Unit Admission

Coexisting conditions and previous antimicrobial drug exposure predict colonization.

[1]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[2]  Jessina C. McGregor,et al.  Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. , 2006, Journal of clinical epidemiology.

[3]  Wonkeun Song,et al.  Prevalence of Newer β-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002 , 2006, Journal of Clinical Microbiology.

[4]  F. Baquero,et al.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). , 2006, The Journal of antimicrobial chemotherapy.

[5]  David L Paterson.  Resistance in gram-negative bacteria: enterobacteriaceae. , 2006, The American journal of medicine.

[6]  Y. Carmeli,et al.  Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  W. Bilker,et al.  Limiting the Emergence of Extended-Spectrum β–Lactamase-Producing Enterobacteriaceae: Influence of Patient Population Characteristics on the Response to Antimicrobial Formulary Interventions , 2006, Infection Control & Hospital Epidemiology.

[8]  Jessina C. McGregor,et al.  Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization , 2005, Emerging infectious diseases.

[9]  J. Decruyenaere,et al.  Colonization Status and Appropriate Antibiotic Therapy for Nosocomial Bacteremia Caused by Antibiotic-Resistant Gram-Negative Bacteria in an Intensive Care Unit , 2005, Infection Control & Hospital Epidemiology.

[10]  X. Bertrand,et al.  Control of Enterobacteriaceae Producing Extended-Spectrum Beta-Lactamase in Intensive Care Units: Rectal Screening May Not Be Needed in Non-Epidemic Situations , 2004, Infection Control & Hospital Epidemiology.

[11]  H. Goossens,et al.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  A. Harris,et al.  Co-Carriage Rates of Vancomycin-Resistant Enterococcus and Extended-Spectrum Beta-Lactamase-Producing Bacteria Among a Cohort of Intensive Care Unit Patients: Implications for an Active Surveillance Program , 2004, Infection Control & Hospital Epidemiology.

[13]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[14]  M. Gardam,et al.  Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? , 2002, The Journal of infectious diseases.

[15]  D. Maki,et al.  The Commonality of Risk Factors for Nosocomial Colonization and Infection with Antimicrobial-Resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida , 2002, Annals of Internal Medicine.

[16]  C. Kelly,et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Kenneth S. Thomson,et al.  Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae , 2001, Antimicrobial Agents and Chemotherapy.

[18]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  L. Rice,et al.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. , 2000, The New England journal of medicine.

[20]  D. Landman,et al.  Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. , 2000, The Journal of antimicrobial chemotherapy.

[21]  T. Marrie,et al.  A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. , 2000, JAMA.

[22]  L. Rice,et al.  Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. , 1999, The Journal of infectious diseases.

[23]  M. Samore,et al.  Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. , 1999, Archives of internal medicine.

[24]  Nina Singh,et al.  Staphylococcus aureus Nasal Colonization in Patients with Cirrhosis: Prospective Assessment of Association with Infection , 1998, Infection Control & Hospital Epidemiology.

[25]  J. Bartlett,et al.  Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  R. Coello,et al.  Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. , 1997, The Journal of hospital infection.

[27]  L. Rice,et al.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  G. Wormser,et al.  Natural History of Colonization with Vancomycin-Resistant Enterococcus Faecium , 1995, Infection Control & Hospital Epidemiology.

[29]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[30]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[31]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[32]  J. Maurer.  Outpatient Care Compared With Hospitalization for Community-Acquired Pneumonia: A Randomized Trial in Low-Risk PatientsCarratalà J, Fernández-Sabé N, Ortega L, et al (Univ of Barcelona; SCIAS-Hosp de Barcelona) Ann Intern Med 142:165–172, 2005§ , 2006 .

[33]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.

[34]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[35]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[36]  J. Ariza,et al.  Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. , 1997, The Journal of hospital infection.